PuSH - Publication Server of Helmholtz Zentrum München

Jakwerth, C.A. ; Feuerherd, M. ; Guerth, F. ; Oelsner, M. ; Schellhammer, L.* ; Giglberger, J. ; Pechtold, L.* ; Jerin, C. ; Kugler, L.* ; Mogler, C.* ; Haller, B.* ; Erb, A. ; Wollenberg, B.* ; Spinner, C.D.* ; Buch, T.* ; Protzer, U. ; Schmidt-Weber, C.B. ; Zissler, U.M. ; Chaker, A.

Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism.

J. Mol. Med. 100, 613-627 (2022)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
SARS-CoV-2 has evolved to enter the host via the ACE2 receptor which is part of the kinin-kallikrein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV-2-infection and epithelial mechanisms of the kinin-kallikrein-system at the kinin B2 receptor level in SARS-CoV-2-infection that is of direct translational relevance. From acute SARS-CoV-2-positive study participants and -negative controls, transcriptomes of nasal curettages were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B2R-antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays, and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model in vivo. Here, we report a broad and strong upregulation of kallikreins and the kinin B2 receptor (B2R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive study participants. A B2R-antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero-E6 cells. B2R-antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2, G protein-coupled receptor signaling, and ion transport in vitro and in a murine airway inflammation in vivo model. In summary, this study provides evidence that treatment with B2R-antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B2R-antagonists, like icatibant, in the treatment of early-stage COVID-19. KEY MESSAGES: Induction of kinin B2 receptor in the nose of SARS-CoV-2-positive patients. Treatment with B2R-antagonist protects airway epithelial cells from SARS-CoV-2. B2R-antagonist reduces ACE2 levels in vivo and ex vivo. Protection by B2R-antagonist is mediated by inhibiting viral replication and spread.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Ace2 ; B2r-antagonist ; Covid-19 ; Kinin ; Kinin-kallikrein-system ; Sars-cov-2; Angiotensin-converting Enzyme-2; Hereditary Angioedema; Bradykinin Formation; Lung; Activation; Cells; Hydrolysis; Pathways; Protein; System
ISSN (print) / ISBN 0946-2716
e-ISSN 1432-1440
Quellenangaben Volume: 100, Issue: 4, Pages: 613-627 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Tiergartenstrasse 17, D-69121 Heidelberg, Germany
Non-patent literature Publications
Reviewing status Peer reviewed
Grants Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft